SCHEMBL3668504

SCHEMBL3668504

Cc1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 14/20 0.75
CDC7 O00311 11/20 0.75
PRKACA P17612 10/20 0.75
CDK2 P24941 9/20 0.75
CLK4 Q9HAZ1 9/20 0.75
PIM1 P11309 8/20 0.75
MKNK2 Q9HBH9 7/20 0.75
MAP4K4 O95819 6/20 0.75
HIPK2 Q9H2X6 4/20 0.75
AURKB Q96GD4 12/20 0.69
ROCK2 O75116 12/20 0.69
CDK5 Q00535 10/20 0.69
DYRK1A Q13627 10/20 0.69
GSK3A P49840 9/20 0.69
ROCK1 Q13464 9/20 0.69
CDK1 P06493 8/20 0.69
PRKCD Q05655 8/20 0.69
CDC42BPA Q5VT25 8/20 0.69
RPS6KA3 P51812 8/20 0.69
AURKA O14965 8/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667859 0.86 CDC7 (1.00) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL27810082 0.85 GSK3B (0.71) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3668887 0.85 PRKACA (0.77) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3670387 0.84 CDC7 (0.72) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3667213 0.83 GSK3B (0.79) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3667795 0.82 PRKACA (1.00) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3665661 0.81 GSK3B (1.00) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3667241 0.80 CDC7 (0.75) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3676069 0.79 CDC7 (1.00) GSK3BCDC7PRKACACDK2CLK4
SCHEMBL3670360 0.78 GSK3B (0.84) GSK3BCDC7PRKACACDK2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885CDC7 8/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GSK3B 1/4885CDC7 8/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.